Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.30
HAE's Cash to Debt is ranked lower than
79% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.75 vs. HAE: 0.30 )
Ranked among companies with meaningful Cash to Debt only.
HAE' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.96 Max: 60.69
Current: 0.3
0.09
60.69
Equity to Asset 0.54
HAE's Equity to Asset is ranked lower than
57% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. HAE: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
HAE' s Equity to Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.65 Max: 0.84
Current: 0.54
0.52
0.84
F-Score: 5
Z-Score: 2.97
M-Score: -3.14
WACC vs ROIC
7.05%
-5.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -6.12
HAE's Operating margin (%) is ranked lower than
64% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. HAE: -6.12 )
Ranked among companies with meaningful Operating margin (%) only.
HAE' s Operating margin (%) Range Over the Past 10 Years
Min: -4.83  Med: 12.55 Max: 16.34
Current: -6.12
-4.83
16.34
Net-margin (%) -7.25
HAE's Net-margin (%) is ranked lower than
65% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. HAE: -7.25 )
Ranked among companies with meaningful Net-margin (%) only.
HAE' s Net-margin (%) Range Over the Past 10 Years
Min: -6.12  Med: 9.12 Max: 11.82
Current: -7.25
-6.12
11.82
ROE (%) -8.81
HAE's ROE (%) is ranked lower than
66% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.61 vs. HAE: -8.81 )
Ranked among companies with meaningful ROE (%) only.
HAE' s ROE (%) Range Over the Past 10 Years
Min: -7.18  Med: 9.87 Max: 12.5
Current: -8.81
-7.18
12.5
ROA (%) -4.81
HAE's ROA (%) is ranked lower than
63% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. HAE: -4.81 )
Ranked among companies with meaningful ROA (%) only.
HAE' s ROA (%) Range Over the Past 10 Years
Min: -3.96  Med: 7.98 Max: 10.03
Current: -4.81
-3.96
10.03
ROC (Joel Greenblatt) (%) -9.55
HAE's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.27 vs. HAE: -9.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HAE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7.84  Med: 28.98 Max: 38.15
Current: -9.55
-7.84
38.15
Revenue Growth (3Y)(%) 1.50
HAE's Revenue Growth (3Y)(%) is ranked lower than
61% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. HAE: 1.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HAE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.4  Med: 8.3 Max: 15
Current: 1.5
-1.4
15
EBITDA Growth (3Y)(%) -27.10
HAE's EBITDA Growth (3Y)(%) is ranked lower than
89% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. HAE: -27.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HAE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.1  Med: 5 Max: 105.5
Current: -27.1
-27.1
105.5
» HAE's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

HAE Guru Trades in Q3 2015

Jim Simons 260,000 sh (+461.56%)
Ken Fisher 208,920 sh (+10.24%)
Joel Greenblatt Sold Out
Barrow, Hanley, Mewhinney & Strauss 2,239,841 sh (-4.12%)
» More
Q4 2015

HAE Guru Trades in Q4 2015

Ken Fisher 219,110 sh (+4.88%)
Barrow, Hanley, Mewhinney & Strauss 1,844,774 sh (-17.64%)
Jim Simons 189,700 sh (-27.04%)
» More
Q1 2016

HAE Guru Trades in Q1 2016

Jim Simons 277,200 sh (+46.13%)
Ken Fisher 219,127 sh (+0.01%)
Barrow, Hanley, Mewhinney & Strauss Sold Out
» More
Q2 2016

HAE Guru Trades in Q2 2016

Paul Tudor Jones 16,898 sh (New)
Joel Greenblatt 39,575 sh (New)
Jim Simons 777,300 sh (+180.41%)
Ken Fisher 257,467 sh (+17.50%)
» More
» Details

Insider Trades

Latest Guru Trades with HAE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:HYH, NAS:ICUI, NAS:NXTM, OTCPK:TOPCF, NAS:PODD, OTCPK:GRRMF, OTCPK:ANSLF, NAS:MMSI, NYSE:GKOS, NAS:ELGX, NAS:LMNX, NAS:ATRI, NYSE:CMN, OTCPK:NNCSF, NAS:NVCR, NAS:ANGO, NAS:ATRC, NAS:OSUR, NAS:MLAB, NAS:STAA » details
Traded in other countries:HAZ.Germany,
Haemonetics Corp is a healthcare company that provides blood management solutions to its customers. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals.

Haemonetics Corp is a Massachusetts corporation founded in 1971. It is a healthcare company that provides blood management solutions to its customers. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helps improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world. The company provide plasma collection systems and software which enable plasma fractionators to make pharmaceuticals and analytical devices for measuring hemostasis. It also makes blood processing systems and softwares for blood donation. Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals. Its product categories include: Plasma, Blood Center, Hospital, and Software Solutions. Plasma includes manufacture and market plasma collection devices and disposables. Blood Center includes automated blood component and manual whole blood collection systems to blood collection centers. Hospital : Loss of blood is common in many surgical procedures, including open heart, trauma, transplant, vascular, and orthopedic procedures, and the need for transfusion of oxygen-carrying red cells to make up for lost blood volume is necessary. Haemonetics offers a range of blood management solutions that improve a hospital's systems for acquiring blood, storing it in the hospital, and dispensing efficiently and perfectly. It also includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions: The company has a suite of integrated software solutions for improving efficiencies and helping ensure donor and patient safety. This includes solutions for blood drive planning, donor recruitment and retention, blood collection, component manufacturing and distribution, transfusion management, and remote blood allocation. The company market and sell their products to bio-pharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations through their own direct sales force (including full-time sales representatives and clinical specialists) as well as independent distributors. The Company's competitors include Terumo BCT, Sorin Biomedica and Fresenius SE & Co. KGaA. The products it manufactures and markets are subject to regulation by the Center of Biologics Evaluation and Research and the Center of Devices and Radiological Health of the United States Food and Drug Administration, and other non-United States regulatory bodies.

Top Ranked Articles about Haemonetics Corp

Weekly CEO Buys Highlights Insiders invest in Penske Automotive, Haemonetics, Gogo, Hanesbrands
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
Forward P/E 22.99
HAE's Forward P/E is ranked higher than
54% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.83 vs. HAE: 22.99 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.59
HAE's P/B is ranked higher than
58% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.07 vs. HAE: 2.59 )
Ranked among companies with meaningful P/B only.
HAE' s P/B Range Over the Past 10 Years
Min: 1.84  Med: 2.55 Max: 3.43
Current: 2.59
1.84
3.43
P/S 2.04
HAE's P/S is ranked higher than
61% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. HAE: 2.04 )
Ranked among companies with meaningful P/S only.
HAE' s P/S Range Over the Past 10 Years
Min: 1.47  Med: 2.4 Max: 3.59
Current: 2.04
1.47
3.59
PFCF 43.27
HAE's PFCF is ranked lower than
72% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.51 vs. HAE: 43.27 )
Ranked among companies with meaningful PFCF only.
HAE' s PFCF Range Over the Past 10 Years
Min: 15.75  Med: 33.62 Max: 486.52
Current: 43.27
15.75
486.52
POCF 12.90
HAE's POCF is ranked higher than
62% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.48 vs. HAE: 12.90 )
Ranked among companies with meaningful POCF only.
HAE' s POCF Range Over the Past 10 Years
Min: 9.91  Med: 14.87 Max: 25.67
Current: 12.9
9.91
25.67
EV-to-EBIT -38.67
HAE's EV-to-EBIT is ranked lower than
99.99% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.49 vs. HAE: -38.67 )
Ranked among companies with meaningful EV-to-EBIT only.
HAE' s EV-to-EBIT Range Over the Past 10 Years
Min: -73.9  Med: 16.3 Max: 71.9
Current: -38.67
-73.9
71.9
EV-to-EBITDA 61.65
HAE's EV-to-EBITDA is ranked lower than
92% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.12 vs. HAE: 61.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
HAE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.1  Med: 11.8 Max: 61.4
Current: 61.65
7.1
61.4
Shiller P/E 45.34
HAE's Shiller P/E is ranked lower than
55% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.84 vs. HAE: 45.34 )
Ranked among companies with meaningful Shiller P/E only.
HAE' s Shiller P/E Range Over the Past 10 Years
Min: 25.95  Med: 34.99 Max: 51.8
Current: 45.34
25.95
51.8
Current Ratio 2.46
HAE's Current Ratio is ranked lower than
51% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. HAE: 2.46 )
Ranked among companies with meaningful Current Ratio only.
HAE' s Current Ratio Range Over the Past 10 Years
Min: 2.17  Med: 3.24 Max: 4.92
Current: 2.46
2.17
4.92
Quick Ratio 1.51
HAE's Quick Ratio is ranked lower than
56% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. HAE: 1.51 )
Ranked among companies with meaningful Quick Ratio only.
HAE' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 2.28 Max: 4.22
Current: 1.51
1.51
4.22
Days Inventory 142.74
HAE's Days Inventory is ranked lower than
60% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.07 vs. HAE: 142.74 )
Ranked among companies with meaningful Days Inventory only.
HAE' s Days Inventory Range Over the Past 10 Years
Min: 89.4  Med: 99.05 Max: 156.73
Current: 142.74
89.4
156.73
Days Sales Outstanding 60.34
HAE's Days Sales Outstanding is ranked higher than
53% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.94 vs. HAE: 60.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
HAE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.47  Med: 68.26 Max: 84.99
Current: 60.34
58.47
84.99
Days Payable 26.29
HAE's Days Payable is ranked lower than
85% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.53 vs. HAE: 26.29 )
Ranked among companies with meaningful Days Payable only.
HAE' s Days Payable Range Over the Past 10 Years
Min: 26.02  Med: 31.36 Max: 41.58
Current: 26.29
26.02
41.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.10
HAE's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. HAE: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HAE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.7  Med: 0.6 Max: 1.9
Current: 0.1
-3.7
1.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.44
HAE's Price/Tangible Book is ranked lower than
70% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. HAE: 7.44 )
Ranked among companies with meaningful Price/Tangible Book only.
HAE' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.69  Med: 3.41 Max: 13.8
Current: 7.44
1.69
13.8
Price/Projected FCF 1.85
HAE's Price/Projected FCF is ranked higher than
54% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.95 vs. HAE: 1.85 )
Ranked among companies with meaningful Price/Projected FCF only.
HAE' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.08  Med: 1.55 Max: 2.56
Current: 1.85
1.08
2.56
Price/Median PS Value 0.85
HAE's Price/Median PS Value is ranked higher than
75% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. HAE: 0.85 )
Ranked among companies with meaningful Price/Median PS Value only.
HAE' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.56  Med: 0.96 Max: 1.43
Current: 0.85
0.56
1.43
Earnings Yield (Greenblatt) (%) -2.60
HAE's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. HAE: -2.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HAE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.4  Med: 6 Max: 11.2
Current: -2.6
1.4
11.2
Forward Rate of Return (Yacktman) (%) -13.09
HAE's Forward Rate of Return (Yacktman) (%) is ranked lower than
87% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.21 vs. HAE: -13.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HAE' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -13.1  Med: 8.95 Max: 17.9
Current: -13.09
-13.1
17.9

More Statistics

Revenue (TTM) (Mil) $905.4
EPS (TTM) $ -1.29
Beta0.94
Short Percentage of Float3.11%
52-Week Range $25.98 - 36.76
Shares Outstanding (Mil)51.04

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 863 877
EPS ($) 1.58 1.52
EPS w/o NRI ($) 1.58 1.52
EPS Growth Rate
(3Y to 5Y Estimate)
15.00%
Dividends Per Share ($)
» More Articles for HAE

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Aug 15 2016 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Meridian Contrarian Fund Second Quarter Commentary Sep 08 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
The Olstein All Cap Value Fund’s 2014 First Quarter Letter to Shareholders Jul 22 2014 
This Blood Management Company Can Be A Safe Investment Jul 13 2014 
Meridian Funds Comments on Haemonetics Aug 28 2013 
Meridian Funds' Second Quarter 2013 Commentary Aug 28 2013 
Weeky CFO Sells Highlight: ADBE, HAE, WAGE, OVTI, ICPT Jun 24 2013 
Allscripts-Misys Reports 5 Insider Buys the Day Before Barclays Conference Mar 13 2013 

More From Other Websites
Weekly CEO Buys Highlights Aug 15 2016
Haemonetics downgraded by Sidoti Aug 15 2016
Haemonetics CEO Completes Open Market Share Purchase Aug 08 2016
Haemonetics CEO Completes Open Market Share Purchase Aug 08 2016
HAEMONETICS CORP Financials Aug 06 2016
ETF’s with exposure to Haemonetics Corp. : August 5, 2016 Aug 05 2016
Haemonetics Corp. :HAE-US: Earnings Analysis: Q1, 2017 By the Numbers : August 4, 2016 Aug 04 2016
Haemonetics (HAE) Lags Q1 Earnings, Tops Sales Estimates Aug 02 2016
Strength seen in Haemonetics (HAE): Stock Soars 10.5% Aug 02 2016
Edited Transcript of HAE earnings conference call or presentation 1-Aug-16 12:00pm GMT Aug 01 2016
Haemonetics Corp Earnings Call scheduled for 8:00 am ET today Aug 01 2016
Q1 2017 Haemonetics Corp Earnings Release - 06:00 am ET Aug 01 2016
Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website Aug 01 2016
Haemonetics Appoints Bill Burke CFO Aug 01 2016
Haemonetics reports 1Q loss Aug 01 2016
Haemonetics reports 1Q loss Aug 01 2016
HAEMONETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Aug 01 2016
Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website Aug 01 2016
Haemonetics Appoints Bill Burke CFO Aug 01 2016
HAEMONETICS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)